Abbrea Capital’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $2.77M | Sell |
8,849
-51
| -0.6% | -$15K | 0.37% | 57 |
|
|
2024
Q1 | $2.53M | Buy |
8,900
+261
| +3% | +$76.4K | 0.33% | 63 |
|
|
2023
Q4 | $2.49M | Buy |
8,639
+285
| +3% | +$77.7K | 0.36% | 63 |
|
|
2023
Q3 | $2.25M | Sell |
8,354
-45
| -0.5% | -$11.2K | 0.36% | 62 |
|
|
2023
Q2 | $1.86M | Buy |
8,399
+322
| +4% | +$74.7K | 0.29% | 78 |
|
|
2023
Q1 | $1.95M | Buy |
8,077
+4
| +0% | +$982 | 0.33% | 68 |
|
|
2022
Q4 | $2.12M | Buy |
8,073
+170
| +2% | +$45.6K | 0.38% | 62 |
|
|
2022
Q3 | $1.78M | Sell |
7,903
-320
| -4% | -$77.6K | 0.34% | 66 |
|
|
2022
Q2 | $2M | Sell |
8,223
-80
| -1% | -$19.6K | 0.33% | 66 |
|
|
2022
Q1 | $2.01M | Hold |
8,303
| – | – | 0.28% | 79 |
|
|
2021
Q4 | $1.87M | Sell |
8,303
-196
| -2% | -$41.4K | 0.25% | 86 |
|
|
2021
Q3 | $1.81M | Buy |
8,499
+360
| +4% | +$82.9K | 0.27% | 81 |
|
|
2021
Q2 | $1.98M | Sell |
8,139
-34
| -0.4% | -$8.36K | 0.3% | 77 |
|
|
2021
Q1 | $2.03M | Buy |
8,173
+99
| +1% | +$23.6K | 0.34% | 68 |
|
|
2020
Q4 | $1.86M | Buy |
8,074
+350
| +5% | +$80.7K | 0.33% | 71 |
|
|
2020
Q3 | $1.96M | Sell |
7,724
-173
| -2% | -$42.9K | 0.42% | 60 |
|
|
2020
Q2 | $1.86M | Sell |
7,897
-432
| -5% | -$98.6K | 0.43% | 60 |
|
|
2020
Q1 | $1.69M | Sell |
8,329
-50
| -0.6% | -$10.9K | 0.45% | 57 |
|
|
2019
Q4 | $2.02M | Buy |
8,379
+45
| +0.5% | +$9.92K | 0.43% | 59 |
|
|
2019
Q3 | $1.61M | Buy |
8,334
+80
| +1% | +$15.4K | 0.37% | 67 |
|
|
2019
Q2 | $1.52M | Buy |
8,254
+2
| +0% | +$358 | 0.37% | 69 |
|
|
2019
Q1 | $1.57M | Buy |
8,252
+752
| +10% | +$144K | 0.45% | 62 |
|
|
2018
Q4 | $1.46M | Buy |
7,500
+315
| +4% | +$61.5K | 0.48% | 59 |
|
|
2018
Q3 | $1.49M | Buy |
7,185
+8
| +0.1% | +$1.58K | 0.44% | 61 |
|
|
2018
Q2 | $1.32M | Buy |
7,177
+215
| +3% | +$38K | 0.42% | 62 |
|
|
2018
Q1 | $1.19M | Buy |
6,962
+732
| +12% | +$134K | 0.38% | 66 |
|
|
2017
Q4 | $1.08M | Sell |
6,230
-61
| -1% | -$10.8K | 0.37% | 74 |
|
|
2017
Q3 | $1.17M | Buy |
6,291
+202
| +3% | +$35.8K | 0.44% | 66 |
|
|
2017
Q2 | $1.05M | Sell |
6,089
-260
| -4% | -$42.3K | 0.42% | 70 |
|
|
2017
Q1 | $1.04M | Sell |
6,349
-130
| -2% | -$21.6K | 0.43% | 70 |
|
|
2016
Q4 | $947K | Buy |
+6,479
| New | +$975K | 0.44% | 66 |
|
Other funds holding AMGN
Abbrea Capital's AMGN Position: Q2 2024 in Review
Abbrea Capital reduced its Amgen (AMGN) stake by 0.57% in Q2 2024, selling an estimated $15K and leaving 8,849 shares worth $2.77M. The position accounts for 0.37% of the portfolio, ranked #57.
Abbrea Capital first reported a position in AMGN in Q4 2016 and has held it in 31 quarters since. 2,785 funds tracked by Wall St. Rank hold AMGN as of Q2 2024.
- Abbrea Capital held 8,849 shares of Amgen worth $2.77M as of Q2 2024.
- Abbrea Capital sold 51 Amgen shares in Q2 2024, an estimated $15K.
- Amgen made up 0.37% of Abbrea Capital's portfolio in Q2 2024, its #57 holding.
- Abbrea Capital first reported a position in Amgen in Q4 2016 and has held it in 31 quarters since.
- 2,785 funds tracked by Wall St. Rank held Amgen as of Q2 2024.
Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.